TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29879133

Group type: EXPERIMENTAL
Intervention: Machine learning models using features from enrollment and level 1 treatment (up to week 2 response) of STAR*D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning models using top 30 features identified via feature selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning models using overlapping features between STAR*D and RIS-INT-93
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early or initial treatment response or symptom severity at week 2
Number of subjects: 0
Study: 29879283

Group type: EXPERIMENTAL
Intervention: Panitumumab plus neoadjuvant chemotherapy (1 dose of panitumumab 2.5 mg/kg followed by 4 cycles of panitumumab 2.5 mg/kg, nab-paclitaxel 100 mg/m2, and carboplatin weekly, then 4 cycles of fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 every 3 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panitumumab plus neoadjuvant chemotherapy
Number of subjects: 40
Study: 29879916

Group type: EXPERIMENTAL
Intervention: Community home-based care intervention
Number of subjects: 682
Study: 29880009

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Guanyuan (CV4), Sanyinjiao (SP6), Taichong (LR3), Zhaohai (KI6) and Qichong (ST30)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Acupuncture at non-acupoints (control group)
Number of subjects: 106
Study: 29880049

Group type: EXPERIMENTAL
Intervention: RiseTx web-based intervention with activity tracker (Jawbone), goal of increasing walking by 3000 daily steps over 12 weeks.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RiseTx web-based intervention
Number of subjects: 46
Study: 29880301

Group type: COMPARATOR
Intervention: Standard disinfection (quaternary ammonium disinfectant, except for C difficile, for which 10% hypochlorite was used)
Number of subjects: 314610

Group type: EXPERIMENTAL
Intervention: Standard disinfection and disinfecting ultraviolet light (UV-C)
Number of subjects: 314610

Group type: EXPERIMENTAL
Intervention: 10% hypochlorite (bleach strategy)
Number of subjects: 314610

Group type: EXPERIMENTAL
Intervention: Bleach and UV-C (bleach and UV strategy)
Number of subjects: 314610
Study: 29880308

Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy
Number of subjects: 81
Study: 29880467

Group type: EXPERIMENTAL
Intervention: Web-based electronic patient-reported outcomes system (ARPEGE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized validated questionnaires (WHOQOL-HIV BREF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usability testing of the electronic patient-reported outcome system
Number of subjects: 0
Study: 29880583

Group type: EXPERIMENTAL
Intervention: BRAF inhibitor treatment, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific treatment not mentioned
Number of subjects: 0
Study: 29880603

Group type: EXPERIMENTAL
Intervention: ibrutinib (n=136)
Number of subjects: 269

Group type: COMPARATOR
Intervention: chlorambucil (n=133)
Number of subjects: 269
Study: 29881615

Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 1647

Group type: EXPERIMENTAL
Intervention: Lactose ingestion
Number of subjects: 1647
Study: 29881616

Group type: COMPARATOR
Intervention: Intervention details not available
Number of subjects: 40
Study: 29881622

Group type: EXPERIMENTAL
Intervention: CAMPROBE biopsy
Number of subjects: 30

Group type: COMPARATOR
Intervention: TRUSBx
Number of subjects: 30
Study: 29881627

Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention programme focusing on nutrition and physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 0
Study: 29881956

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement therapy (NRT) 14 or 21 mg per day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29882017

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg, single dose) administered after an overnight fast on day 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg) administered with omeprazole (40 mg) on day 7
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omeprazole (40 mg) administered alone on days 3-6, 1 hour before breakfast
Number of subjects: 20
Study: 29882098

Group type: EXPERIMENTAL
Intervention: Surgeon-Performed Ultrasound (SPUS) for gallstones
Number of subjects: 300

Group type: COMPARATOR
Intervention: Radiologist-Performed Ultrasound (RPUS) for gallstones
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Surgeon-Performed Ultrasound (SPUS) for acute cholecystitis
Number of subjects: 300

Group type: COMPARATOR
Intervention: Radiologist-Performed Ultrasound (RPUS) for acute cholecystitis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Surgeon-Performed Ultrasound (SPUS) for appendicitis
Number of subjects: 300

Group type: COMPARATOR
Intervention: Radiologist-Performed Ultrasound (RPUS) for appendicitis
Number of subjects: 300
Study: 29882481

Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (30 million)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (50 million)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (70 million)
Number of subjects: 12
Study: 29882693

Group type: EXPERIMENTAL
Intervention: Preoperative physiologic passive knee HE ≥5°
Number of subjects: 1145

Group type: COMPARATOR
Intervention: No preoperative physiologic passive knee HE ≥5° (non-HE group)
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Use of allograft
Number of subjects: 1145
Study: 29883936

Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29884187

Group type: EXPERIMENTAL
Intervention: Standard term infant formula enriched with alpha-lactalbumin, exclusively fed for 6 weeks
Number of subjects: 40
Study: 29884204

Group type: EXPERIMENTAL
Intervention: ≥ 5 CTCs at baseline
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ≥ 1 CTC cluster at baseline
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Longitudinal evaluation of CTCs and CTC clusters
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Changes in CTCs during treatment
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Decline from ≥ 5 CTCs at baseline to < 5 CTCs at 1 month
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: CTC clusters presence
Number of subjects: 156

Group type: COMPARATOR
Intervention: Prognostic model based on clinicopathological variables
Number of subjects: 156
Study: 29884223

Group type: EXPERIMENTAL
Intervention: Biotherapy after first Anti-TNF treatment failure
Number of subjects: 0

Group type: COMPARATOR
Intervention: First Anti-TNF treatment
Number of subjects: 0
Study: 29884234

Group type: EXPERIMENTAL
Intervention: Endometriosis Symptom Diary (ESD)
Number of subjects: 272
Study: 29884620

Group type: EXPERIMENTAL
Intervention: Ablation that terminated persistent AF prior to pulmonary vein isolation
Number of subjects: 55
Study: 29884695

Group type: EXPERIMENTAL
Intervention: PCV10 in a 3+1 schedule
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PCV10 in a 3+0 schedule
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PCV10 in a 2+1 schedule
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PCV10 in a two-dose schedule
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PCV13 in a 2+1 schedule
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group receiving two doses of PCV10 at 18 and 24 months
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group of 200 children receiving one dose of PCV10 at 24 months
Number of subjects: 1200
Study: 29885373

Group type: EXPERIMENTAL
Intervention: Staged approach with endobronchial ultrasound (EBUS) followed by EMN-bronchoscopy (ENB) and EMN-transthoracic biopsy (EMN-TTNA)
Number of subjects: 150
Study: 29885469

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 25
Study: 29885765

Group type: EXPERIMENTAL
Intervention: Model based on spectral analysis of ventricular fibrillation (VF) ECG tracings
Number of subjects: 0
Study: 29885861

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex
Number of subjects: 0
Study: 29885885

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) injection intravenously at the end of endometriosis resection.
Number of subjects: 3
Study: 29885904

Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 737

Group type: COMPARATOR
Intervention: Haloperidol 5 mg
Number of subjects: 737

Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 737

Group type: COMPARATOR
Intervention: Ziprasidone 20 mg
Number of subjects: 737
Study: 29885989

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 33
Study: 29886024

Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg or 75 mg orally every 12 hours for 3 days plus one morning (part A) or 24 weeks (part B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg orally every 12 hours for 24 weeks (part B)
Number of subjects: 26
Study: 29886154

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg daily for 12 weeks
Number of subjects: 79
Study: 29886204

Group type: EXPERIMENTAL
Intervention: Self-reported anxiety symptoms assessed by the GAD-7 questionnaire in MDD subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subjective cognitive impairment assessed by the Perceived Deficits Questionnaire for Depression-5-item in MDD subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-reported difficulties caused by anxiety in MDD subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-reported difficulties with anxiety in MDD subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Objective cognitive performance assessed by the THINC-it tool in MDD subjects
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 100
Study: 29886411

Group type: COMPARATOR
Intervention: Enhanced Care (EC) - Standard Care plus cell phone-delivered messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive Care (IC) - Enhanced Care plus cell phone-delivered counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive Care (IC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Number of subjects: 0
Study: 29886425

Group type: EXPERIMENTAL
Intervention: Poor sleep quality (Pittsburgh Sleep Quality Index score ≥5)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea risk (Berlin questionnaire)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Insomnia (Insomnia Severity Index)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Sleep duration (actigraphy in subset of n=26)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (n=26)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Overall sleep duration
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 323
Study: 29886446

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fenestration
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open-release surgery
Number of subjects: 64
Study: 29886522

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 464
Study: 29886724

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 478
Study: 29888205

Group type: EXPERIMENTAL
Intervention: Axitinib in combination with best supportive care (BSC)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo in combination with best supportive care (BSC)
Number of subjects: 202
Study: 29888811

Group type: EXPERIMENTAL
Intervention: PAQ (wearable 3-day insulin delivery device)
Number of subjects: 28
Study: 29889229

Group type: EXPERIMENTAL
Intervention: fT3
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: fT3/fT4 ratio
Number of subjects: 321

Group type: COMPARATOR
Intervention: TSH
Number of subjects: 321

Group type: COMPARATOR
Intervention: fT4
Number of subjects: 321
Study: 29889671

Group type: EXPERIMENTAL
Intervention: Pre-epiglottic space thickness measured with ultrasound (mDSE cut-off value of 2.54 cm)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Pre-epiglottic area measured with ultrasound (cut-off value of 5.04 cm)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: mDSE in female patients
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: mDSE in male patients
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ultrasound assessments at the level of vocal cords
Number of subjects: 301
Study: 29889751

Group type: EXPERIMENTAL
Intervention: Outpatient transcervical catheter placement
Number of subjects: 129

Group type: COMPARATOR
Intervention: Inpatient transcervical catheter placement with concomitant oxytocin infusion
Number of subjects: 129
Study: 29889830

Group type: EXPERIMENTAL
Intervention: Renal Resistive Index (RRI) measured on ICU admission
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: RRI for AKI stage 2
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: RRI for AKI stage 3
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: RRI for AKI stage 1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Univariate analysis of RRI
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of RRI
Number of subjects: 99
Study: 29889987

Group type: EXPERIMENTAL
Intervention: Parental assessment using a three-item visual analogue scale (VAS) concerning Activity, Feeding, and Illness.
Number of subjects: 267
Study: 29890123

Group type: EXPERIMENTAL
Intervention: Weston CAC score
Number of subjects: 1875

Group type: EXPERIMENTAL
Intervention: Agatston CAC score
Number of subjects: 1875

Group type: COMPARATOR
Intervention: Baseline CAD
Number of subjects: 1875

Group type: COMPARATOR
Intervention: Incident CVD
Number of subjects: 1875
Study: 29890128

Group type: EXPERIMENTAL
Intervention: Mifepristone treatment for 3 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Endometrium not displaying PAEC (control group)
Number of subjects: 11
Study: 29890186

Group type: EXPERIMENTAL
Intervention: BOLD response in the medial prefrontal cortex for anticipating food compared to money
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: BOLD response in the dorsolateral prefrontal cortex for winning food compared to money
Number of subjects: 59
Study: 29890238

Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 0
Study: 29890330

Group type: EXPERIMENTAL
Intervention: Vascular Space Occupancy (VASO) imaging at 9.4 T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29890508

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 226
Study: 29890892

Group type: EXPERIMENTAL
Intervention: Group sequential procedure based on the asymptotic covariance of the sequence of Wald statistics
Number of subjects: 4600

Group type: EXPERIMENTAL
Intervention: Group sequential procedure based on the canonical joint distribution
Number of subjects: 4600
Study: 29890960

Group type: EXPERIMENTAL
Intervention: Mentalisation-based treatment (MBT)
Number of subjects: 75
Study: 29891238

Group type: EXPERIMENTAL
Intervention: s-cTnI Architect
Number of subjects: 2601

Group type: EXPERIMENTAL
Intervention: s-cTnI Ultra
Number of subjects: 2601

Group type: EXPERIMENTAL
Intervention: s-cTnI Accu
Number of subjects: 2601

Group type: EXPERIMENTAL
Intervention: hs-cTnI Accu
Number of subjects: 2601
Study: 29891470

Group type: EXPERIMENTAL
Intervention: Integrated and personalized practitioner-led method (gene test results plus integrated and personalized nutrition report)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (gene test results report emailed)
Number of subjects: 55
Study: 29891609

Group type: EXPERIMENTAL
Intervention: Intravenous solithromycin (6 to 8 mg/kg of body weight)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral solithromycin (14 to 16 mg/kg on days 1 and 7; 10 to 15 mg/kg on days 2 to 5)
Number of subjects: 84
Study: 29891610

Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg
Number of subjects: 0
Study: 29891853

Group type: COMPARATOR
Intervention: Methylated DNA markers (MDMs) assessed by quantitative methylation specific PCR (qMSP) on tissue samples.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Whole esophageal brushings with selected MDMs.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Capsule sponge (25 mm, 10 pores or 20 pores per inch) swallowed by patients.
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2-marker panel (VAV3 + ZNF682) for BE discrimination.
Number of subjects: 62
Study: 29892208

Group type: EXPERIMENTAL
Intervention: Procarbazine and CCNU chemotherapy
Number of subjects: 8
Study: 29893698

Group type: EXPERIMENTAL
Intervention: Serum Hemoglobin (Hb) levels in patients with NAFLD
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Patients with NAFLD
Number of subjects: 1186
Study: 29893797

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1pdm09 vaccine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Seasonal vaccinations (repeated and occasional groups)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Single group (no seasonal vaccination)
Number of subjects: 250
Study: 29895073

Group type: EXPERIMENTAL
Intervention: G-POEM
Number of subjects: 20
Study: 29895178

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV/MVA-BN-Filo prime-boost Ebola vaccine regimen
Number of subjects: 0
Study: 29895247

Group type: EXPERIMENTAL
Intervention: Hippocampal mean diffusivity (MD) measured by Diffusion-Tensor Imaging in primary care patients
Number of subjects: 140

Group type: COMPARATOR
Intervention: Hippocampal mean diffusivity (MD) measured by Diffusion-Tensor Imaging in specialized care patients
Number of subjects: 140
Study: 29895259

Group type: EXPERIMENTAL
Intervention: Real stimulation using CTU Mega 20 device (200 J, 2 Tesla)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real stimulation using CTU Mega 20 device
Number of subjects: 0
Study: 29895331

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) as first-line treatment
Number of subjects: 584

Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 584

Group type: COMPARATOR
Intervention: Limiting life-sustaining measures
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Intubation after NIV
Number of subjects: 584
Study: 29895612

Group type: EXPERIMENTAL
Intervention: Patients employed at baseline who reported an adverse change in employment after MI (n=492)
Number of subjects: 9319

Group type: EXPERIMENTAL
Intervention: Patients with an adverse change in employment (n=492)
Number of subjects: 9319
Study: 29895651

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation for neuropsychiatric symptoms (NPSs) management
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 200
Study: 29895668

Group type: EXPERIMENTAL
Intervention: Preinfusion CAR product T-cell functionality (measured by T-cell polyfunctionality strength index - PSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preinfusion CAR product T-cell expansion and pretreatment serum IL-15 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyfunctional CD4 T-cells within the total product cell population
Number of subjects: 0
Study: 29895702

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 100
Study: 29895713

Group type: EXPERIMENTAL
Intervention: Complex coronary lesion geometries (longitudinal eccentricity, cross-sectional eccentricity, surface roughness)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Distal longitudinal eccentricity
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Visual-functional mismatch between coronary angiography and FFR
Number of subjects: 1236
Study: 29896154

Group type: EXPERIMENTAL
Intervention: Levosulpiride (75 mg/day orally TID) for 8 weeks (DME and NPDR), 1 week (PDR before vitrectomy), or 12 weeks (DME plus ranibizumab)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (lactose pill, orally TID)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levosulpiride (75 mg/day orally TID)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29896450

Group type: EXPERIMENTAL
Intervention: Training program (8-h intensive short-course)
Number of subjects: 176
Study: 29896479

Group type: EXPERIMENTAL
Intervention: Rye kernel bread (RKB) evening meals
Number of subjects: 19

Group type: COMPARATOR
Intervention: White wheat bread (WWB) evening meals
Number of subjects: 19
Study: 29896663

Group type: EXPERIMENTAL
Intervention: Oncolytic virotherapy using herpes simplex virus (HSV)
Number of subjects: 0
Study: 29897474

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity index (ISI)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Estimated 24-hour LH levels
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Estimated 24-hour insulin level
Number of subjects: 11
Study: 29897482

Group type: EXPERIMENTAL
Intervention: Cryptosporidiosis infection (subclinical)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Cryptosporidiosis
Number of subjects: 508
Study: 29897486

Group type: EXPERIMENTAL
Intervention: Br-E (Habitual breakfast eaters)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Br-S (Habitual breakfast skippers)
Number of subjects: 32
Study: 29897529

Group type: EXPERIMENTAL
Intervention: CFS scores 3-4
Number of subjects: 6156

Group type: EXPERIMENTAL
Intervention: CFS scores 5-7
Number of subjects: 6156

Group type: EXPERIMENTAL
Intervention: CFS classes added to EuroSCORE II
Number of subjects: 6156
Study: 29897579

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Low plasma vitamin B-12
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Other micronutrient status biomarkers
Number of subjects: 1042
Study: 29897841

Group type: EXPERIMENTAL
Intervention: CYD-TDV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29898218

Group type: EXPERIMENTAL
Intervention: Martin/Hopkins method for LDL-C estimation
Number of subjects: 12742

Group type: EXPERIMENTAL
Intervention: Friedewald method for LDL-C estimation
Number of subjects: 12742

Group type: EXPERIMENTAL
Intervention: Correlation with PUC LDL-C
Number of subjects: 12742